Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 6:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1249–1272 of 1,836 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo- C Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 1

NCT01594320
View directory record Official record
Conditions
Influenza (Pandemic)
Interventions
Monovalent Avian Influenza VLP (H5N1), Monovalent Avian Influenza VLP (H5N1); Adjuvant, Saline placebo
Biological
Lead sponsor
Novavax
Industry
Eligibility
18 Years to 49 Years
Enrollment
333 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
5
States / cities
Anaheim, California • Miami, Florida • Pembroke Pines, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2014 · Synced Oct 30, 2026, 6:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluating Drug Interactions Between Doravirine With Estradiol and Spironolactone in Healthy Transgender Women

NCT04283656
View directory record Official record
Conditions
Transgender Health, Gender Dysphoria, Transgender Women, Human Immunodeficiency Virus
Interventions
Doravirine/Lamivudine/Tenofovir, Spironolactone 100mg, Estradiol 2mg, Placebo
Drug · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 26, 2025 · Synced Oct 30, 2026, 6:56 PM EDT
Completed Early Phase 1 Interventional

Exercise and NO in HFrEF

NCT03136029
View directory record Official record
Conditions
Heart Failure With Reduced Ejection Fraction
Interventions
Antioxidant, Tetrahydrobiopterin (BH4), Exercise training
Dietary Supplement · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Oct 30, 2026, 6:56 PM EDT
Completed Phase 1Phase 2 Interventional

Study Assessing PTI-428 Safety, Tolerability, and Pharmacokinetics in Subjects With Cystic Fibrosis

NCT02718495
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
PTI-428, Placebo
Drug
Lead sponsor
Proteostasis Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
20
States / cities
Stanford, California • Altamonte Springs, Florida • Gainesville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2019 · Synced Oct 30, 2026, 6:56 PM EDT
Terminated Phase 2 Interventional

A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)

NCT06881251
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Dupilumab, JNJ-95475939, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
13
States / cities
Fountain Valley, California • Los Angeles, California • Alpharetta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 30, 2026, 6:56 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of OMT on Functional Outcomes and Anti-inflammatory Biomarkers in Mild to Moderate Traumatic Brain Injury

NCT03163901
View directory record Official record
Conditions
Vestibular Disorder, Headache, Traumatic Brain Injury
Interventions
Osteopathic Manipulative Treatment
Other
Lead sponsor
Michigan State University
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Mason, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 24, 2020 · Synced Oct 30, 2026, 6:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Xla1 Christensenella Minuta, Phase I, Randomized, Partially Placebo-controlled Double-blind Protocol, Evaluating Safety, Tolerability and Impact on the Gut Microbiota in Healthy Volunteers, Overweight and Obese Adults

NCT04663139
View directory record Official record
Conditions
Obesity, Metabolic Disease
Interventions
Xla1, Placebo
Drug
Lead sponsor
YSOPIA Bioscience
Industry
Eligibility
19 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced Oct 30, 2026, 6:56 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation and Treatment of Copper/Zinc Imbalance in Children With Autism

NCT00325572
View directory record Official record
Conditions
Autism, Pervasive Developmental Disorder
Interventions
oral zinc and vitamin C supplements, oral Placebo
Drug · Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
3 Years to 8 Years
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 17, 2019 · Synced Oct 30, 2026, 6:56 PM EDT
Completed Not applicable Interventional

Vitamin C Supplement for Lumbar Spine Surgery

NCT03918694
View directory record Official record
Conditions
Lumbar Spine Surgery
Interventions
Vitamin C, Placebo
Dietary Supplement
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
45 Years to 80 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Oct 30, 2026, 6:56 PM EDT
Completed Phase 2 Interventional Results available

Phase II Study to Analyze Sarilumab in Non-Infectious Uveitis

NCT01900431
View directory record Official record
Conditions
Uveitis
Interventions
Sarilumab, Prednisone, Methotrexate, Folic/folinic acid, Placebo (for Sarilumab)
Drug · Other
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
5
States / cities
Worcester, Massachusetts • Omaha, Nebraska • Slingerlands, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Oct 30, 2026, 6:56 PM EDT
Completed Phase 2 Interventional

Combining TLR9 Agonist With bNAbs for Reservoir Reduction and Immunological Control of HIV

NCT03837756
View directory record Official record
Conditions
HIV-1-infection
Interventions
Saline, Lefitolimod, 3BNC117 and 10-1074
Drug
Lead sponsor
University of Aarhus
Other
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 23, 2023 · Synced Oct 30, 2026, 6:56 PM EDT
Completed Phase 2 Interventional

Clinical Study of Ensifentrine-Glycopyrrolate (MK-5884A/RPL554) Fixed-dose Combination Dose Ranging in Participants With COPD (MK-5884A-029/RPL554-CO-212)

NCT07016412
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Ensifentrine 3 mg, Glycopyrrolate 21.25 mcg, Glycopyrrolate 42.5 mcg, Placebo
Drug
Lead sponsor
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Industry
Eligibility
40 Years to 80 Years
Enrollment
497 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
57
States / cities
Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 30, 2026, 6:56 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Nitrate and Vitamin C on Vascular Health Oxidative Stress

NCT04283630
View directory record Official record
Conditions
Endothelial Dysfunction
Interventions
Dietary nitrate in the form of beetroot juice for all participnats, Nature Made vitamin c 1000 mg, Placebo
Dietary Supplement
Lead sponsor
David Travis Thomas
Other
Eligibility
50 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Oct 30, 2026, 6:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Effect of RO4917838 on the QTcF Interval in Healthy Volunteers

NCT01613040
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Moxifloxacin, RO4917838, RO4917838 placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
169 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 30, 2026, 6:56 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A(H7N9) VLP Antigen Dose-Ranging Study With Matrix-M1™ Adjuvant

NCT02078674
View directory record Official record
Conditions
Influenza (Pandemic)
Interventions
Monovalent Avian Influenza VLP (H7N9), Matrix-M1™ adjuvant, Placebo
Biological
Lead sponsor
Novavax
Industry
Eligibility
18 Years to 64 Years
Enrollment
610 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
5
States / cities
Walnut Creek, California • Miami, Florida • Meridian, Idaho + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2016 · Synced Oct 30, 2026, 6:56 PM EDT
Completed Phase 1 Interventional

A Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Modified Vaccinia Ankara (MVA)-Mosaic OR Ad26.Mos4.HIV Plus a Combination of Mosaic and Clade C gp140 Protein in Human Immunodeficiency Virus (HIV) Type 1 Infected Adults on Suppressive Antiretroviral Treatment

NCT03307915
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
Ad26.Mos4.HIV, MVA-Mosaic, Clade C gp140 + Mosaic gp140, Placebo
Biological · Drug
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 30, 2026, 6:56 PM EDT
Active, not recruiting Phase 3 Interventional

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)

NCT04241185
View directory record Official record
Conditions
Urinary Bladder Neoplasms
Interventions
Pembrolizumab, Conventional Radiotherapy (Bladder only), Conventional Radiotherapy (Bladder and pelvic nodes), Hypofractionated Radiotherapy (Bladder only), Cisplatin, Fluorouracil (5-FU), Mitomycin C (MMC), Gemcitabine, Placebo to Pembrolizumab
Drug · Radiation
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
24
States / cities
Washington D.C., District of Columbia • Bay Pines, Florida • Orlando, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 30, 2026, 6:56 PM EDT
Completed Phase 1 Interventional

Randomized, Placebo-controlled, 2 Period, Single-blind, Sequential, Multiple Ascending Dose Study

NCT01956305
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
DS-7309, placebo, Metformin
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 24, 2014 · Synced Oct 30, 2026, 6:56 PM EDT
Terminated Phase 2 Interventional Results available

A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation

NCT02156076
View directory record Official record
Conditions
Paroxysmal Atrial Fibrillation
Interventions
BMS-919373, Placebo (Matching with BMS-919373)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
Not listed
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
20
States / cities
Anaheim, California • Costa Mesa, California • Long Beach, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Oct 30, 2026, 6:56 PM EDT
Not listed Phase 1 Interventional

Ursodiol in Huntington's Disease

NCT00514774
View directory record Official record
Conditions
Huntington Disease
Interventions
ursodiol, placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 5, 2009 · Synced Oct 30, 2026, 6:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and PK of Nikkomycin Z in Healthy Subjects

NCT00834184
View directory record Official record
Conditions
Healthy
Interventions
nikkomycin Z
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 40 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Oct 30, 2026, 6:56 PM EDT
Completed Phase 2 Interventional

A Phase II Study of the Safety and Efficacy of MPSK3169A in Patients With Coronary Heart Disease or High Risk of Coronary Heart Disease

NCT01609140
View directory record Official record
Conditions
Coronary Heart Disease
Interventions
MPSK3169A, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
34
States / cities
Goodyear, Arizona • Carmichael, California • Spring Valley, California + 29 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 30, 2026, 6:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Salmonella Conjugates CVD 1000: Study of Responses to Vaccination With Trivalent Invasive Salmonella Disease Vaccine

NCT03981952
View directory record Official record
Conditions
Risk Reduction
Interventions
Trivalent Invasive Salmonella Disease Vaccine (6.25 µg), Trivalent Invasive Salmonella Disease Vaccine (12 µg), Trivalent Invasive Salmonella Disease Vaccine (25 µg), Trivalent Invasive Salmonella Disease Vaccine (highest, well-tolerated dose among Cohorts A-C), Placebo
Biological · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 45 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Oct 30, 2026, 6:56 PM EDT
Completed Phase 2 Interventional

Effect of CP-778,875 on HDL-C in Subjects With Abnormal Lipid Levels and Type 2 Diabetes.

NCT00326326
View directory record Official record
Conditions
Dyslipidemia
Interventions
CP-778,875
Drug
Lead sponsor
Pfizer
Industry
Eligibility
30 Years to 70 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
31
States / cities
Anniston, Alabama • Huntsville, Alabama • Greenbrae, California + 26 more
Source: ClinicalTrials.gov public record
Updated May 7, 2009 · Synced Oct 30, 2026, 6:56 PM EDT